<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.apple-converted-space
{mso-style-name:apple-converted-space;}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.EmailStyle21
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle23
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:211506898;
mso-list-template-ids:-141493496;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:402067756;
mso-list-template-ids:-115051170;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DHS-2D19-2D002.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=wNUuMuWKRL6T_xAQ3Q8cKnaWI2qpZA6828nUvYQnM-Q&s=t0sLWkOEjN0RP3B9drnxCzmhQZH6BPkew1z0PhM8khI&e=" target="_blank">Using Data Analytics to Support Primary Care and Community Interventions to Improve Chronic Disease
Prevention and Management and Population Health (R18)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The purpose of this FOA is to invite applications to promote health equity and improve the health of individuals and populations at risk for suboptimal health outcomes through the use of primary
care and community interventions that address chronic conditions, including prevention and management of multiple chronic conditions. This is to be accomplished by developing data resources, applying health services research methodologies and presenting data
analytics to primary care providers, health care delivery systems, public health departments, and/or community organizations to help them address social determinants of health (SDOH) and contribute to the delivery of whole person, 360-degree care that meets
physical, behavioral, and oral health, as well as social services, needs.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due May 29, 2019.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: May 14.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:red"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:red"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DHS-2D19-2D003.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=wNUuMuWKRL6T_xAQ3Q8cKnaWI2qpZA6828nUvYQnM-Q&s=KTVUPTN1R7gANMcIpAY5EQTmpF_Qm5iOEp61CzrfQHQ&e=" target="_blank">AHRQ Health Services Research Project: Partners Enabling Diagnostic Excellence (R01)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The purpose of this funding opportunity announcement (FOA) is to fund investigative health services research projects that establish the incidence of diagnostic errors, enhance our understanding
of the factors contributing to diagnostic errors, and the association between diagnostic safety and quality and outcomes such as patient harms, costs, expenditures, and utilization.As an HHS Operating Division, AHRQ is committed to addressing the HHS
<a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.hhs.gov_about_leadership_secretary_priorities_index.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=wNUuMuWKRL6T_xAQ3Q8cKnaWI2qpZA6828nUvYQnM-Q&s=o2PiY4cProgwba95pr45XlZd1YO71nI3g2G9a9fmLkc&e="><span style="color:black">Secretary’s priorities</span></a> and encourages applicants to address one or more of the Secretary’s priorities. Of those priorities, this funding opportunity
announcement is likely to be most relevant to addressing the opioid crisis and patient safety aspects of value-based care.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due May 29, 2019.</span></b><span style="font-family:Palatino;color:black">
</span><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: May 14.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:red"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.aacr.org_Funding_Pages_Funding-2DDetail.aspx-3FItemID-3D90&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=wNUuMuWKRL6T_xAQ3Q8cKnaWI2qpZA6828nUvYQnM-Q&s=ug7B_td8y7ueyqAUM-OZRpAMgx27kPC5g8iRc2ObJIA&e=" target="_blank">Overview</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The American Association for Cancer Research, in partnership with healthcare investment firm MPM Capital, is inviting Letters of Intent for its Oncology Charitable Foundation Transformative
Cancer Research Grants program. A new funding initiative, the program is intended to stimulate high-risk, high-reward research by early- to mid-career investigators and promote and support creative, paradigm-shifting cancer research that might not be funded
through conventional channels. It is expected that grants awarded through the program will catalyze significant scientific discoveries that advance understanding of cancer and have a potentially transformative impact on future clinical practice.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">Though the program, grants of up to $400,000 over two years will be awarded for any type of basic, translation, or clinical research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Letter of intent due May 10, 2019.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: April 29.</span></b><b><span style="font-family:Palatino;color:black"><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__lalorfound.org_anna-2Dlalor-2Dburdick-2Dprogram_application-2Dguidelines_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=wNUuMuWKRL6T_xAQ3Q8cKnaWI2qpZA6828nUvYQnM-Q&s=9lI6-iSDr4bAo8L-w-ymI8kQZF3mDBlN-pUkE_1JL3I&e=" target="_blank">Lalor Foundation: Advancing Research and Innovation in Reproductive Health</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The Anna Lalor Burdick (ALB) Program supports programs that offer sexual and reproductive health education to young women. It is interested in programs serving young women who are disadvantaged
by poverty, discrimination, geographic isolation, lack of comprehensive sex education, hostile public policy, or other factors leading to inadequate sexual and reproductive health.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The ALB Program is particularly interested in supporting
<b>new programs</b> or initiatives, or <b>innovations in successful programs</b>. Programs at new or small organizations, including those with a grassroots base, that are capable of delivering excellent services will also be considered.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The ALB Program awards a small number of grants in the range of $10,000 to $35,000, with an average grant size between $15,000 and $25,000. Grants are awarded for one year.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Concept papers due May 1, 2019 and November 1, 2019.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for May deadline: April 22.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.pfizer.com_sites_default_files_rfp-5Ffiles_GMG-5FQI-5FRFE-2D19-2DCV.pdf&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=wNUuMuWKRL6T_xAQ3Q8cKnaWI2qpZA6828nUvYQnM-Q&s=dLDaQxmkYys7NZfI3-Ic_rPCNul5s2VXKGFBMn9u_XI&e=">Bristol-Myers Squibb/Pfizer Alliance Independent Medical Education/Global Medical Grant: Quality Improvement
Initiatives for Undiagnosed Nonvalvular Atrial Fibrillation (NVAF)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">This program will support Quality Improvement (QI) initiatives that focus on decreasing the number of people with undiagnosed/ untreated NVAF (i.e., diagnosed but not anticoagulated as per
guidelines) within healthcare teams, especially those with increased risk factors, such as age ≥65 years, heart failure (left ventricular dysfunction), hypertension, diabetes, prior stroke or embolism, and vascular disease (peripheral vascular disease, prior
MI, or aortic plaque). Of specific interest are QI initiatives that increase awareness of the burden and consequences of the undiagnosed/untreated NVAF (i.e., diagnosed but not anticoagulated as per guidelines) population and provide tools to improve identification
of undiagnosed NVAF and help reduce risk of preventable stroke. <o:p></o:p></span></p>
<p class="MsoNormal" style="font-variant-caps: normal;orphans: auto;text-align:start;widows: auto;-webkit-text-size-adjust: auto;-webkit-text-stroke-width: 0px;word-spacing:0px">
<b><span style="font-family:Palatino;color:black">Due May 7, 2019.<span class="apple-converted-space"> </span></span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: April 23.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:red"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.alzdiscovery.org_research-2Dand-2Dgrants_funding-2Dopportunities_digital-2Dbiomarkers&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=wNUuMuWKRL6T_xAQ3Q8cKnaWI2qpZA6828nUvYQnM-Q&s=qB_3wRZDQuzQOfJtVzEd8Oe6irXhjPGthv4QiMB6C-M&e=" target="_blank">Alzheimer’s Drug Discovery Foundation / Diagnostics Accelerator: Digital Biomarkers</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">Through this RFP, ADDF seeks proposals for the development and validation of digital biomarkers for Alzheimer’s disease and related dementias. Digital biomarkers are defined as objective, quantifiable
physiological and behavioral data that are collected, measured, and analyzed by means of digital devices such as portables, wearables, or ambient sensors. They can range from computerized or app-based versions of traditional neurocognitive tests to novel technology
platforms that combine multiple complex data sources into a phenotypic signature.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">Proposals addressing a range of potential clinical uses are of interest, especially technologies for early assessment and those aiding in diagnosis and monitoring treatment response or rate
of disease progression. Creative approaches that leverage new and existing software and hardware are encouraged. The use of the digital technology should be driven by 1) an unmet patient or scientific need for a better assessment; and/or 2) providing a more
cost-effective, efficient, and less burdensome approach to diagnosis and monitoring in clinical practice and clinical trials.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">Symptom domains of interest include but are not limited to cognition (e.g., memory, processing speed, executive function, or geolocation); speech and language (e.g., written text or vocal features);
activities of daily living (instrumental basic activities or higher-order activities); motor function (e.g., gait, body motion, or fine motor skills, including tapping, swiping, and tracing on touchscreens); sensory acuity (e.g., hearing, smell); affect (e.g.,
mood, facial expression); sleep patterns and characteristics; occulomotor (e.g., eye movement); pain assessment; and/or autonomic nervous function (e.g., heart rate, galvanic skin response). Three project stages will be supported through this RFP:<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Exploratory awards:</span></b><span style="font-family:Palatino;color:black"> Awards of awarded up to $250,000 (based on stage and scope of research) will support pilot studies that aim
to test the utility of an existing digital technology for the first time in Alzheimer’s disease or a related dementia population. Projects should already have preliminary human data from another disease indication. Only proposals with evidence demonstrating
that the technology or prototype can reliably capture, process, store, and transfer data from a clinical population will be considered. A limited number of awards will be considered in this category.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Proof-of-principle awards:
</span></b><span style="font-family:Palatino;color:black">Awards of up to $500,000 (based on stage and scope of research) will support projects that demonstrate feasibility and/or verify that a certain approach has potential for use in Alzheimer’s disease or
related dementias. Preliminary data from human subjects with the proposed indication is expected and must demonstrate that the technology or prototype is capable of the reliable capture, processing, storage, and transfer of valid data to test in the clinical
population<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Validation awards:</span></b><span style="font-family:Palatino;color:black"> These awards will support projects that require testing at a larger scale as well as access to patients of varying
demographic diversity to demonstrate clinical relevance. The technology must be verified and validated, and data quantifying the accuracy, precision, consistency, and uniformity of the technology must be provided. Applicants will be required to address scalability
considerations, clinical integration plans, and anticipated regulatory considerations and commercialization. Data sharing policies and standards, intellectual property restrictions, and standard operating procedures should be well defined. Validation studies
should prioritize comparisons using existing gold standard approaches to diagnose and monitor such as neuroimaging and/or CSF measurements, as well as clinical tests such as cognition, but this is dependent on the context of use. These studies will require
a comprehensive experimental plan with larger sample size (e.g. 500-1000+ subjects based on power analyses). Award amounts will be based on the stage and scope of the research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Letter of Intent due June 7, 2019.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: May 23.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:#2E75B6"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D222.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=wNUuMuWKRL6T_xAQ3Q8cKnaWI2qpZA6828nUvYQnM-Q&s=tx4-iqfQBbs2AiDVsiC8gxs3fK2DsuMmeckQfTJGZ50&e=" target="_blank"><span style="color:#2E75B6">Small Grants for New Investigators to Promote Diversity in Health-Related
Research (R21 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The purpose of this Funding Opportunity Announcement (FOA) is to provide support for New Investigators: (1) from diverse backgrounds, including from groups nationally underrepresented in biomedical
and behavioral research to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Human Genome Research Institute (NHGRI) and (2) who at the time of award
under this FOA will have/have had less than $125,000 direct cost of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources
and seeks to facilitate the transition to research independence of diverse New Investigators. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research
projects; development of research methodology; and development of new research technology.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Standard dates apply. Expires May 8, 2022.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for June deadline: June 3.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:#2E75B6"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DCA-2D19-2D034.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=wNUuMuWKRL6T_xAQ3Q8cKnaWI2qpZA6828nUvYQnM-Q&s=Fs6ZYwLVZ7IeHUcMYF8PboIjkyXzrb4RjPaB9LyTuUY&e=" target="_blank"><span style="color:#2E75B6">Feasibility and Planning Studies for Development of Specialized Programs
of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional)</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants
will support feasibility and planning activities to build comprehensive cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized
Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect
specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">All the proposed P20 programs must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources
core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due June 19, 2019; October 18, 2019; June 19, 2020; and October 18, 2020.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for June deadline: June 5.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.pva.org_research-2Dfoundation&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=wNUuMuWKRL6T_xAQ3Q8cKnaWI2qpZA6828nUvYQnM-Q&s=mU4GBtlHob4sBtV6D-O3SUP4gwiK9GUVHdq5VBHb1bg&e=" target="_blank">Paralyzed Veterans of America Research Fellowships and Grants: Spinal Cord Injury and Disease</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">From transplanting cells and regenerating damaged nerve fibers to designing adaptive canoe seats, the Paralyzed Veterans of America Research Foundation supports innovative research and fellowships
that improve the lives of those with spinal cord injury and disease (SCI/D). The Research Foundation, a 501(c)(3) nonprofit, funds the following categories:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo3"><b><span style="font-family:Palatino">Basic Science</span></b><span style="font-family:Palatino"> - laboratory research in the basic sciences to find a cure for SCI/D<o:p></o:p></span></li><li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo3"><b><span style="font-family:Palatino">Clinical</span></b><span style="font-family:Palatino"> - clinical and functional studies of the medical, psychosocial and economic effects of SCI/D, and
interventions to alleviate these effects<o:p></o:p></span></li><li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo3"><b><span style="font-family:Palatino">Design and Development</span></b><span style="font-family:Palatino"> - of assistive technology for people with SCI/D, which includes improving the identification,
selection and utilization of these devices<o:p></o:p></span></li><li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo3"><b><span style="font-family:Palatino">Fellowships</span></b><span style="font-family:Palatino"> - for postdoctoral scientists, clinicians and engineers to encourage training and specialization
in the field of spinal cord research<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due July 1, 2019.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: June 17.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span><span style="color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e="><span style="font-family:Palatino;color:#954F72">CoM’s
unofficial funding opportunities blog</span></a></span></b><b><span style="font-family:Palatino;color:black">.</span></b><span style="color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>